Pulmonology Pulmonology
Pulmonol 2018;24:10-5 - Vol. 24 Num.1 DOI: 10.1016/j.rppnen.2017.10.008
Original article
Effectiveness and safety of varenicline and nicotine replacement therapy among mental health patients: A retrospective cohort study
C.A. Jimenez-Ruiza,, , J.F. Pascual-Lledób, A. Cícero-Guerreroa, M. Cristóbal-Fernándeza, M. Mayayo-Ulibarria, C. Villar-Lagunaa
a Smoking Cessation Service, Region of Madrid, Madrid, Spain
b Respiratory Medicine Department, Hospital Universitario, Alicante, Spain
Received 11 June 2017, Accepted 21 October 2017

To analyse the effectiveness and safety of two smoking cessation medications (varenicline and nicotine patches) in patients with controlled psychiatric disorders in daily practice in a Smoking Cessation Service.


This is a retrospective cohort study. It was carried on at a smoking cessation clinic in Madrid and used a convenience sampling strategy. We reviewed medical records of patients diagnosed with psychiatric disorders who attended a Smoking Cessation Service. All patients received similar treatment programme: a combination of pharmacological treatment (varenicline or nicotine replacement therapy) and intensive cognitive-behavioural therapy.


The group included 349 patients (38.4% men). Mean age (SD) 49.6 (10.5) years. 28.3 (12.8) cigarettes per day. 156 subjects achieved 9–24 weeks continuous abstinence (44.7%), in 39% of those who used nicotine patches and in 53.7% of those who used varenicline. OR: 1.64 (95% CI: 1.03–2.61; p=0.036). Success rates were higher in men; OR 1.85 (95% CI: 1.12–3.04; p=0.016). High levels of CO and high daily cigarette use were associated with poorer success rates (OR: 0.98, 95% CI: 0.96–0.99, p=0.007; and OR: 0.98, 95% CI: 0.96–1.00, p=0.045), respectively. Nausea and pruritus were the most common adverse events. No cases of suicidal ideation or behaviour were found.


Varenicline and nicotine patches could be safe and effective smoking cessation treatments for patients with psychiatric disorders in daily clinical practice.

Smoking, Treatment, Psychiatric disorder, Varenicline, Nicotine patch
Pulmonol 2018;24:10-5 - Vol. 24 Num.1 DOI: 10.1016/j.rppnen.2017.10.008
Cookies Policy
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.